The matrix metalloproteinase-7 polymorphism RS10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1330-1335

  Jaboin, Jerry J ^a   Hwang, Misun ^a   Lopater, Zachary ^a   Chen, Heidi ^a   Ray, Geoffrey L ^c   Perez, Carmen ^a   Cai, Qiuyin ^b   Wills, Marcia L ^a   Lu, Bo ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Matrilysin; Matrix metalloproteinase 7; Polymorphism; Prognosis; Prostate cancer

Indexed keywords

ADJUVANT RADIATION; CONFIDENCE INTERVAL; COX REGRESSION ANALYSIS; GENOTYPING; LOCAL CONTROL; LOCALIZED PROSTATE CANCER; LYMPH NODE; MARGIN STATUS; MATRILYSIN; MATRIX METALLOPROTEINASE-7; MATRIX METALLOPROTEINASES; MULTI VARIABLES; OVERALL SURVIVAL; PROGNOSIS; PROGNOSTIC FACTORS; PROSTATE CANCER; PROSTATE CANCER RECURRENCE; PROSTATE CANCERS; PROSTATE TISSUE; RADICAL PROSTATECTOMY; RANK TEST; RECURRENCE-FREE SURVIVAL; RISK MATRIX; RISK STRATIFICATION; SINGLE NUCLEOTIDE POLYMORPHISMS;

DIAGNOSIS; GENES; NUCLEOTIDES; PARAFFIN WAXES; PARAFFINS; PATIENT MONITORING; RADIOTHERAPY; RATING; REGRESSION ANALYSIS; UROLOGY;

DISEASES;

MATRILYSIN;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 79952706154     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.013     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Parekh DJ, Ankerst DP, Troyer D, et al. Biomarkers for prostate cancer detection. J Urol 2007;178:2252-2259. (Pubitemid 350052199)
3. Shariat SF, Karam JA, Margulis V, et al. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008;101:675-683. (Pubitemid 351269995)
4. Miyazaki K, Hattori Y, Umenishi F, et al. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res 1990;50:7758-7764.
5. Quantin B, Murphy G, Breathnach R. Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 1989;28:5327-5334. (Pubitemid 19175740)
6. Sellers A, Woessner JF Jr. The extraction of a neutral metalloproteinase from the involuting rat uterus, and its action on cartilage proteoglycan. Biochem J 1980;189:521-531.
7. Wilson CL, Matrisian LM. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-136. (Pubitemid 26072499)
8. Woessner JF Jr., Taplin CJ. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. J Biol Chem 1988;263:16918-16925. (Pubitemid 18268875)
9. Cardillo MR, Di Silverio F, Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006;26:973-982.
10. Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993;53:417-422. (Pubitemid 23031858)
11. Knox JD, Wolf C, McDaniel K, et al. Matrilysin expression in human prostate carcinoma. Mol Carcinog 1996;15:57-63. (Pubitemid 26072884)
12. Hashimoto K, Kihira Y, Matuo Y, et al. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998;160:1872-1876. (Pubitemid 128746778)
13. Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:886-891. (Pubitemid 46910086)
14. Singh H, Jain M, Mittal B. MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol Oncol 2008;110:71-75.
15. Ghilardi G, Biondi ML, Erario M, et al. Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms. Clin Chem 2003;49:1940-1942. (Pubitemid 37340333)
16. Li Y, Jin X, Kang S, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 2006;101:92-96.
17. Vairaktaris E, Serefoglou Z, Yapijakis C, et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 2007;27:2493-2498. (Pubitemid 47228094)
18. Zhang J, Jin X, Fang S, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005;26:1748-1753. (Pubitemid 41487990)
19. Beeghly-Fadiel A, Long JR, Gao YT, et al. Common MMP-7 polymorphisms and breast cancer susceptibility: A multistage study of association and functionality. Cancer Res 2008;68:6453-6459.
20. American Joint Committee on Cancer. Prostate. In: AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 309-316.
21. Browning RE 4th, Li H, Shinohara ET, et al. ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer. Urology 2006;67:1320-1323. (Pubitemid 43818064)
22. Li HC, Albert JM, Shinohara ET, et al. E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urol Oncol 2006;24:496-502. (Pubitemid 44810010)
23. Beeghly-Fadiel A, Shu XO, Long J, et al. Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer 2008;124:208-214.
24. Hughes S, Agbaje O, Bowen RL, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007;13:6673-6680. (Pubitemid 350206803)
25. Kubben FJ, Sier CF, Meijer MJ, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 2006;95:744-751. (Pubitemid 44373491)
26. Sugimoto M, Furuta T, Kodaira C, et al. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J Gastroenterol 2008;43:751-761.
27. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149. (Pubitemid 30123793)
28. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22:145-152. (Pubitemid 36561054)
29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174. (Pubitemid 37328786)
30. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-1821. (Pubitemid 37533251)